Mark G. Kris

100.9k total citations · 39 hit papers
661 papers, 62.4k citations indexed

About

Mark G. Kris is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Mark G. Kris has authored 661 papers receiving a total of 62.4k indexed citations (citations by other indexed papers that have themselves been cited), including 443 papers in Pulmonary and Respiratory Medicine, 386 papers in Oncology and 131 papers in Molecular Biology. Recurrent topics in Mark G. Kris's work include Lung Cancer Treatments and Mutations (398 papers), Lung Cancer Research Studies (196 papers) and Lung Cancer Diagnosis and Treatment (152 papers). Mark G. Kris is often cited by papers focused on Lung Cancer Treatments and Mutations (398 papers), Lung Cancer Research Studies (196 papers) and Lung Cancer Diagnosis and Treatment (152 papers). Mark G. Kris collaborates with scholars based in United States, Japan and United Kingdom. Mark G. Kris's co-authors include Vincent A. Miller, Gregory J. Riely, William Pao, Maureen F. Zakowski, Marc Ladanyi, Maria E. Arcila, Valerie W. Rusch, Harold Varmus, Richard J. Gralla and Camelia S. Sima and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Mark G. Kris

646 papers receiving 60.7k citations

Hit Papers

EGF receptor gene mutatio... 1991 2026 2002 2014 2004 2005 2003 2013 2015 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
    2004 3.5k citations William Pao, Vincent A. Miller et al. profile →
  2. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
    2005 2.8k citations William Pao, Vincent A. Miller et al. profile →
  3. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
    2003 2.1k citations Mark G. Kris et al. profile →
  4. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
    2013 1.9k citations Helena A. Yu, Maria E. Arcila et al. Clinical Cancer Research profile →
  5. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
    2015 1.7k citations Ethan Basch, Mark G. Kris et al. Journal of Clinical Oncology profile →
  6. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
    2005 1.2k citations William Pao, Gregory J. Riely et al. profile →
  7. TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
    2005 1.2k citations Mark G. Kris, Vincent A. Miller et al. Journal of Clinical Oncology profile →
  8. Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
    2000 1.1k citations Vincent A. Miller, Mark G. Kris et al. Journal of Clinical Oncology profile →
  9. Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer
    1991 1.1k citations Gary H. Lyman, Mark G. Kris et al. profile →
  10. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
    2011 827 citations Ethan Basch, Ann Alexis Prestrud et al. Journal of Clinical Oncology profile →
  11. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases
    2011 757 citations Gregory J. Riely, Mark G. Kris et al. profile →
  12. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    2000 665 citations Maureen F. Zakowski, Mark G. Kris et al. profile →
  13. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
    2006 664 citations Marissa N. Balak, Yixuan Gong et al. Clinical Cancer Research profile →
  14. ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial
    2002 646 citations Mark G. Kris et al. Journal of Clinical Oncology profile →
  15. Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
    2009 644 citations William Pao, Gregory J. Riely et al. Journal of Clinical Oncology profile →
  16. Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
    2004 628 citations Vincent A. Miller, Mark G. Kris et al. Journal of Clinical Oncology profile →
  17. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
    2006 623 citations Gregory J. Riely, William Pao et al. Clinical Cancer Research profile →
  18. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.
    1998 606 citations Mark G. Kris et al. Journal of Clinical Oncology profile →
  19. Serpins Promote Cancer Cell Survival and Vascular Co-Option in Brain Metastasis
    2014 601 citations Jamie E. Chaft, Mark G. Kris et al. profile →
  20. HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
    2012 555 citations Maria E. Arcila, Yelena Y. Janjigian et al. Cancer Discovery profile →
  21. Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
    2005 518 citations Mark G. Kris et al. Journal of Clinical Oncology profile →
  22. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
    2006 516 citations Mark G. Kris, Paul J. Hesketh et al. Journal of Clinical Oncology profile →
  23. Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations
    2011 503 citations Paul K. Paik, Maria E. Arcila et al. Journal of Clinical Oncology profile →
  24. Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS -Mutant Cancers
    2012 493 citations Ronglai Shen, Daphne Ang et al. Clinical Cancer Research profile →
  25. Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
    2010 485 citations Geoffrey R. Oxnard, Maria E. Arcila et al. Clinical Cancer Research profile →
  26. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
    1999 483 citations Mark G. Kris, Paul J. Hesketh et al. Journal of Clinical Oncology profile →
  27. Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes
    2009 480 citations Ethan Basch, Glenn Heller et al. profile →
  28. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
    2011 476 citations Maria E. Arcila, Geoffrey R. Oxnard et al. Clinical Cancer Research profile →
  29. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
    2014 416 citations Matthew D. Hellmann, Jamie E. Chaft et al. profile →
  30. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
    2017 397 citations Paul J. Hesketh, Mark G. Kris et al. Journal of Clinical Oncology profile →
  31. Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas
    2012 366 citations Maria E. Arcila, Jamie E. Chaft et al. Clinical Cancer Research profile →
  32. Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
    2013 350 citations Ethan Basch, Mark G. Kris et al. Journal of Clinical Oncology profile →
  33. EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
    2013 348 citations Maria E. Arcila, Khédoudja Nafa et al. Molecular Cancer Therapeutics profile →
  34. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
    2016 327 citations Alexander Drilon, Natasha Rekhtman et al. profile →
  35. High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
    2019 289 citations Charles M. Rudin, Maria E. Arcila et al. Clinical Cancer Research profile →
  36. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
    2019 271 citations Adam J. Schoenfeld, Kathryn C. Arbour et al. profile →
  37. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update
    2017 235 citations Mark G. Kris, Jamie E. Chaft et al. Journal of Clinical Oncology profile →
  38. Antiemetics: ASCO Guideline Update
    2020 224 citations Paul J. Hesketh, Mark G. Kris et al. Journal of Clinical Oncology profile →
  39. Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
    2021 222 citations Jamie E. Chaft, Christopher G. Azzoli et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mark G. Kris 38.5k 36.3k 16.7k 9.4k 7.3k 661 62.4k
Jaap Verweij 22.3k 0.6× 28.2k 0.8× 13.7k 0.8× 5.6k 0.6× 8.8k 1.2× 621 55.4k
Howard I. Scher 34.1k 0.9× 22.8k 0.6× 18.2k 1.1× 13.7k 1.5× 7.9k 1.1× 804 63.5k
Roy S. Herbst 26.5k 0.7× 31.9k 0.9× 17.0k 1.0× 9.2k 1.0× 2.6k 0.4× 583 50.9k
Seth M. Steinberg 13.6k 0.4× 29.1k 0.8× 15.6k 0.9× 7.9k 0.8× 6.4k 0.9× 864 58.9k
Frances A. Shepherd 32.9k 0.9× 31.4k 0.9× 12.2k 0.7× 7.3k 0.8× 3.1k 0.4× 671 49.5k
James Chih‐Hsin Yang 33.9k 0.9× 46.1k 1.3× 18.4k 1.1× 9.4k 1.0× 3.0k 0.4× 698 66.2k
Bernard Escudier 26.8k 0.7× 14.5k 0.4× 22.9k 1.4× 14.0k 1.5× 4.1k 0.6× 717 41.8k
Bruce E. Johnson 29.3k 0.8× 29.7k 0.8× 20.8k 1.2× 9.7k 1.0× 2.5k 0.3× 420 50.6k
Larry Rubinstein 20.2k 0.5× 22.4k 0.6× 9.1k 0.5× 7.3k 0.8× 7.3k 1.0× 196 47.6k
David Cunningham 30.7k 0.8× 42.1k 1.2× 12.7k 0.8× 6.5k 0.7× 24.5k 3.3× 1.2k 77.9k

Countries citing papers authored by Mark G. Kris

Since Specialization
Citations

This map shows the geographic impact of Mark G. Kris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark G. Kris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark G. Kris more than expected).

Fields of papers citing papers by Mark G. Kris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark G. Kris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark G. Kris. The network helps show where Mark G. Kris may publish in the future.

Co-authorship network of co-authors of Mark G. Kris

This figure shows the co-authorship network connecting the top 25 collaborators of Mark G. Kris. A scholar is included among the top collaborators of Mark G. Kris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark G. Kris. Mark G. Kris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Choudhury, Noura J., Adam J. Schoenfeld, Jessica Flynn, et al.. (2021). Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. Clinical Cancer Research. 27(10). 2920–2927. 47 indexed citations
2.
Yu, Helena A., Ken Suzawa, Emmet Jordan, et al.. (2018). Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clinical Cancer Research. 24(13). 3108–3118. 188 indexed citations
3.
Arbour, Kathryn C., Hyunjae R. Kim, Jordan Dienstag, et al.. (2017). Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 24(2). 334–340. 317 indexed citations
4.
Gallant, Jean‐Nicolas, Jonathan H. Sheehan, Timothy M. Shaver, et al.. (2015). EGFR Kinase Domain Duplication ( EGFR -KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Cancer Discovery. 5(11). 1155–1163. 81 indexed citations
5.
Drilon, Alexander, Lu Wang, Maria E. Arcila, et al.. (2015). Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clinical Cancer Research. 21(16). 3631–3639. 202 indexed citations
6.
Drilon, Alexander, Romel Somwar, Jacob P. Wagner, et al.. (2015). A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1 -Rearranged Lung Cancer. Clinical Cancer Research. 22(10). 2351–2358. 128 indexed citations
7.
Arcila, Maria E., Khédoudja Nafa, Jamie E. Chaft, et al.. (2013). EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics. Molecular Cancer Therapeutics. 12(2). 220–229. 348 indexed citations breakdown →
8.
Suehara, Yoshiyuki, Maria E. Arcila, Lu Wang, et al.. (2012). Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions. Clinical Cancer Research. 18(24). 6599–6608. 132 indexed citations
9.
Rekhtman, Natasha, Paul K. Paik, Maria E. Arcila, et al.. (2012). Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR / KRA S and Presence of PIK3CA / AKT1 Mutations. Clinical Cancer Research. 18(4). 1167–1176. 289 indexed citations
10.
Pietanza, M. Catherine, Kyuichi Kadota, Kety Huberman, et al.. (2012). Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker. Clinical Cancer Research. 18(4). 1138–1145. 122 indexed citations
11.
Oxnard, Geoffrey R., Binsheng Zhao, Camelia S. Sima, et al.. (2011). Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes. Journal of Clinical Oncology. 29(23). 3114–3119. 118 indexed citations
12.
Basch, Ethan, Ann Alexis Prestrud, Paul J. Hesketh, et al.. (2011). Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 29(31). 4189–4198. 827 indexed citations breakdown →
13.
Oxnard, Geoffrey R., Yelena Y. Janjigian, Maria E. Arcila, et al.. (2011). Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib. Clinical Cancer Research. 17(19). 6322–6328. 50 indexed citations
14.
Arcila, Maria E., Geoffrey R. Oxnard, Khédoudja Nafa, et al.. (2011). Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay. Clinical Cancer Research. 17(5). 1169–1180. 476 indexed citations breakdown →
15.
Chaft, Jamie E., Maria E. Arcila, Paul K. Paik, et al.. (2011). Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling. Molecular Cancer Therapeutics. 11(2). 485–491. 162 indexed citations
16.
Paik, Paul K., Maria E. Arcila, Michael Fara, et al.. (2011). Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations. Journal of Clinical Oncology. 29(15). 2046–2051. 503 indexed citations breakdown →
17.
Zhao, Binsheng, Geoffrey R. Oxnard, Chaya S. Moskowitz, et al.. (2010). A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development. Clinical Cancer Research. 16(18). 4647–4653. 82 indexed citations
18.
Girard, Nicolas, Emil Lou, Christopher G. Azzoli, et al.. (2010). Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report. Clinical Cancer Research. 16(2). 755–763. 70 indexed citations
19.
Girard, Nicolas, Ronglai Shen, Tianhua Guo, et al.. (2009). Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas. Clinical Cancer Research. 15(22). 6790–6799. 147 indexed citations
20.
Balak, Marissa N., Yixuan Gong, Gregory J. Riely, et al.. (2006). Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors. Clinical Cancer Research. 12(21). 6494–6501. 664 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jaap Verweij Breakdown of academic impact, for papers by Howard I. Scher Breakdown of academic impact, for papers by Roy S. Herbst Breakdown of academic impact, for papers by Seth M. Steinberg Breakdown of academic impact, for papers by Frances A. Shepherd Breakdown of academic impact, for papers by James Chih‐Hsin Yang Breakdown of academic impact, for papers by Bernard Escudier Breakdown of academic impact, for papers by Bruce E. Johnson Breakdown of academic impact, for papers by Larry Rubinstein Breakdown of academic impact, for papers by David Cunningham
Rankless by CCL
2026